Elevance Health, Inc. (ELV) Analyst Ratings & Price Targets

Elevance Health, Inc.

ELV · NYSE

Analyst Consensus

Buy

20 analysts

$424

Current

—

Low

$455

Average

—

High

Average target implies +7.25% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across 20 analysts, with a mean target of $455 against the latest stated price of $378.00. The supplied data do not report a low or high target, so target clustering and the width of the spread cannot be measured. No named analyst or firm is identified as the most bullish or least bullish, and no individual target is supplied for comparison. The record also contains no analyst revisions during the past week, preventing a conclusion about whether estimates moved higher or lower. The substantive documented disagreement is therefore limited: consensus is uniformly positive, while the range, dispersion and revision trend remain unavailable.

Rating Actions

No individual rating actions have been captured for ELVyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

CANTOR FITZGERA

CLEVELAND RESEA

CO FORECST

DEUTSCHE BK SEC

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

LOOP CAPITAL MK

MIZUHO SECURITI

NEPHRON RESEARC

RBC CAPITAL

SANFORD BERNSTE

STEPHENS INC

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: ELV
Type: Stock
Sector: Health Care
Industry: Hospital & Medical Service Plans
Exchange: NYSE

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey - connecting them to the care, support, and resources they need to lead better lives. Elevance Health's companies serve approximately 105 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions.

Key Issues

Bullish view

Revenue increased to $199.1 billion in FY2025 from $177.0 billion in FY2024, showing substantial top-line expansion.

Bearish view

Net income fell to $5.7 billion from $6.0 billion over the same period, indicating that growth did not translate into higher earnings.

Analyst Consensus

See all

Buy

20 analysts

$424

Current

—

Low

$455

Average

—

High

Average target implies +7.25% versus the current price.

Earnings History

BeatMissNo estimate

Elevance Health, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Covering Firms

Peers